Barriers to and facilitators of the use of oxygen therapy in people living with an interstitial lung disease: a systematic review of qualitative evidence

Gabriella Tikellis; Mariana Hoffman; Christie Mellerick; Angela T Burge; Anne E Holland

doi:10.1183/16000617.0066-2023

Barriers to and facilitators of the use of oxygen therapy in people living with an interstitial lung disease: a systematic review of qualitative evidence

Eur Respir Rev. 2023 Aug 23;32(169):230066. doi: 10.1183/16000617.0066-2023. Print 2023 Sep 30.

Authors

Gabriella Tikellis^{1

2}, Mariana Hoffman³, Christie Mellerick³, Angela T Burge^{3

4}, Anne E Holland^{3

2

4

5}

Affiliations

¹ Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Australia gabriella.tikellis@monash.edu.
² NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Sydney, Australia.
³ Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Australia.
⁴ Department of Physiotherapy, Alfred Health, Melbourne, Australia.
⁵ Institute for Breathing and Sleep, Melbourne, Australia.

Abstract

Background: Oxygen therapy is prescribed to treat hypoxaemia in people with interstitial lung disease (ILD); however, uptake and adherence remain an ongoing challenge. This systematic review aimed to identify the barriers to and facilitators of use of oxygen therapy in people with ILD, caregivers and health professionals.

Methods: A systematic search for qualitative literature was undertaken using five electronic databases (MEDLINE, CINAHL, Embase, PsycINFO, PubMed). Qualitative analysis identified themes that were mapped to the Theoretical Domains Framework and the Consolidated Framework for Implementation Research and classified as barriers, facilitators or both.

Results: A total of 13 studies were eligible for inclusion. Commonly represented domains were associated with the design of the oxygen delivery system, the associated cost, financing, stigmatisation, the physical environment and the individual needs that acted as barriers to and facilitators of the optimisation of oxygen therapy.

Conclusion: Effective implementation of oxygen therapy in ILD requires more robust evidence to strengthen international guidelines, sustainable and equitable funding models, and improved oxygen delivery systems that meet the needs of users. Increased information and support for users will be critical to optimise the uptake and outcomes of this important therapy.

Publication types

Systematic Review
Review

MeSH terms

Environment
Health Personnel
Humans
Lung Diseases, Interstitial* / diagnosis
Lung Diseases, Interstitial* / therapy
Oxygen
Oxygen Inhalation Therapy* / adverse effects

Substances

Oxygen